Marker Therapeutics, Inc. (MRKR) Year-over-year earnings per share growth for the last twelve months

MRKR (Marker Bio) - company brandmark

FDA orphan status and a network of partner centers keep leukemia patients within the Marker Therapeutics (MRKR) ecosystem. A proprietary high-tech facility in Texas ensures stable drug production. Innovative T-cell therapy without genetic modification promises affordable cancer treatment. Quarterly earnings per share changes visualize business efficiency, where the 19.90 level indicates the parameter's status.

Marker Therapeutics, Inc. (MRKR) - Year-over-year earnings per share growth for the last 12 months from 07/04/2022 to 11/18/2026

MRKR (Marker Therapeutics, Inc.): analytical breakdowns and indicator data

- market value and analyst target forecast:
Summary company analytics:Marker Therapeutics
Flagship merchandise of markertherapeutics.com

Marker Therapeutics' high expenditures on leukemia therapy clinical trials and regular equity dilution through share issuances exert significant pressure on its financial stability. The quarterly growth dynamics of net earnings per share quantify the efficiency of managing these costs by measuring the percentage change in profit over three months, allowing the current quarterly EPS trend to isolate the fundamental signal from market noise.

Competitor analysis

tgtherapeutics.com (TGTX) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Arcellx Therapeutics (ACLX)|Year-over-year earnings per share growth for the last twelve months Disc Medicine Inc|Earnings per share growth in annualized terms for the last twelve months Syndax Pharmaceuticals SNDX|Quarterly EPS earnings growth KURA|ADC Therapeutics SA - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth FHTX (Foghorn Therapeutics, Inc.)|Vor Bio Inc. (VOR) - Earnings per share growth in annualized terms for the last twelve months|NKTX - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months coeptistx.com|ATNM (Actinium Pharmaceuticals) - Year-over-year net earnings per share growth for the last 12 months|ESLA: Year-over-year earnings per share growth rate for the last twelve months|CASI (CASI Pharmaceuticals, Inc.) - Quarterly EPS earnings growth|Quarterly EPS earnings growth IN8bio, Inc.|Year-over-year earnings per share growth for the last twelve months Eterna Therapeutics Inc (ERNA)|Year-over-year net earnings per share change for the last twelve months gtbiopharma.com|Quarterly EPS earnings growth APTO (Aptose Biosciences)|Quarterly EPS earnings growth Bio-Path BPTH|MEI Pharma Inc - Quarterly EPS earnings growth|VINC (Vincerx Pharma Inc.) - Year-over-year earnings per share growth for the last 12 months